Moxonidine is a centrally active imidazoline receptor agonist that effectively lowers blood pressure and has been shown to have beneficial effects on lipid and carbohydrate metabolism. We assessed the efficacy of moxonidine in a postmarketing surveillance study (CAMUS) conducted in 772 practices in Germany, documenting 4005 patients with hypertension, who were overweight and/or suffered from metabolic syndrome. Patients were treated with moxonidine (Cynt s ) for the first time following the baseline visit for 8 weeks. Mean blood pressure decreased from 168/97 to 141/83 mmHg for all patients and from 168/96 to 141/83 mmHg for patients with metabolic syndrome. Blood pressure reduction was particularly pronounced in patients with severe hypertension at baseline. The response rate (DBPp90 mmHg or reduction X10 mmHg) of antihypertensive treatment with moxonidine was 94.0% for all patients and 93.8% for patients with metabolic syndrome. The recommended targets for antihypertensive treatment of the German Diabetes Society/German Hypertension Society were reached by 30.5% of nondiabetics (goal: o140/90 mmHg) and by 3.6% of diabetics (goal: o130/80 mmHg) observed. After 8 weeks of treatment, patients achieved a mean weight loss of 1.4 kg, which was particularly pronounced in obese patients. The rate of patients receiving antihypertensive combination therapy was 81.1% for those with metabolic syndrome, and 63.3% for all other patients. Patients with metabolic syndrome were preferentially treated with ACE inhibitors and diuretics. We conclude that moxonidine effectively reduces blood pressure in patients with metabolic syndrome while simultaneously reducing body weight in obese patients.
Introduction
Since its recognition as early as 1966 by Camus, the metabolic syndrome (also known as the insulin resistance syndrome or syndrome X) has been repeatedly described by several authors. [1] [2] [3] [4] Although there are a number of different definitions of this syndrome, the most common definition used in Europe is that of the WHO, which includes the presence of type II diabetes mellitus or impaired glucose tolerance and two of the following abnormalities: abdominal obesity, essential hypertension, dyslipidemia with low high-density lipoprotein (HDL) cholesterol, hypertriglyceridemia, and/or microalbuminuria. 5 While the various components have long been identified as cardiovascular risk factors, 6, 7 recent studies have shown that the metabolic syndrome, as defined by the WHO, is associated with a 2.6 to 3-fold relative risk for cardiovascular mortality. 8 The presence of the metabolic syndrome is also highly predictive for the development of type II diabetes. 9 Recent studies have highlighted the importance of adequate blood-pressure control in patients with type II diabetes. [10] [11] [12] Based on these observations, the target blood pressure for patients with diabetes has recently been lowered to o130/80 in recent guidelines from the WHO, 13 the German Diabetes Society, 14 and the German Hypertension Society, particularly in patients with microalbumiuria or overt diabetic nephropathy.
As documented in recent studies, most patients with the metabolic syndrome will require combination therapy, often including drugs other than those recommended for first-line therapy. 15 The centrally active imidazoline receptor agonist moxonidine is a sympatholytic drug that effectively lowers blood pressure, [16] [17] [18] [19] [20] is well tolerated, and has been shown to have beneficial effects on lipid and carbohydrate metabolism and insulin sensitivity. [21] [22] [23] While the efficacy and safety of moxonidine has been previously documented in a postmarketing surveillance study, 24 its effect has not been previously examined in patients who were overweight and/or had the metabolic syndrome. We therefore examined the efficacy and safety of moxonidine in these patients within the framework of a postmarketing surveillance study in Germany.
Materials and methods

Patients
CAMUS was conducted as an observational postmarketing surveillance study in a convenience sample of general practitioners, internists, and diabetologists in Germany. Male and female patients with essential hypertension, who were assessed by the physician as being overweight or obese and/or having the metabolic syndrome, were prospectively followed. Patients previously treated with moxonidine were excluded. In patients not on antihypertensive medication, blood pressure levels were required to be 4140 mmHg (systolic) and/or 490 mmHg (diastolic). The metabolic syndrome was diagnosed based on the WHO definition (Table 1 ). There were no further restrictions regarding antihypertensive therapy for enrolment. Physicians were referred to the product information for moxonidine for information on contraindications.
Monitoring
Patient data were recorded at baseline, at 4 and at 8 weeks following commencement of moxonidine. All patients were started on moxonidine after the baseline visit. Baseline data included demographic and disease variables. The diagnosis of a metabolic syndrome was assessed based on the WHO definition ( Table 1) . Each of these parameters was documented separately by the physicians (present, absent, not assessed), except for BMI, which was calculated based on height and body weight. Classification into patients with and without metabolic syndrome was done in the statistical analysis. The initial dose of moxonidine as well as all concomitant antihypertensive medication was recorded and changes were documented at each visit. Blood pressure, heart rate, body weight, WHR, and adverse events were likewise documented at each visit.
What is known:
• Moxonidine is a sympatholytic drug that effectively lowers blood pressure.
• Most hypertensive patients need combination therapy.
What is new:
• Moxonidine is as effective in lowering blood pressure in hypertensive patients with the metabolic syndrome, as in patients without this syndrome.
• Overweight patients with the metabolic syndrome are more likely to be on combination therapy.
• Overweight patients with the metabolic syndrome were more likely to be on ACE inhibitors and diuretics than patients without the metabolic syndrome.
• Despite good blood pressure response to moxonidine and more frequent use of combination therapy, less than 5% of diabetic patients achieve blood pressure target (<130/80 mmHg).
Data quality and statistics
In order to ensure data quality, a predefined data validation plan was implemented. This included rechecking of predefined variables, exploratory statistics for consistency, and a comparison of the data to the Lilly Pharmacovigilance Database.
All data were analysed by descriptive statistics. All outcome variables were analysed with regard to changes at 8 weeks from baseline (95% confidence intervals). Responders were defined as patients with diastolic blood pressure o90 mmHg or decrease 410 mmHg, and as the proportion of patients who reached the target blood pressure defined by the German Diabetes Society/German Hypertension Society.
The following subgroup analyses were also performed: presence of metabolic syndrome (yes/no), severity of hypertension at baseline; degree of overweight/obesity, degree of congestive heart failure (NYHA), previous antihypertensive medication (yes/no), and antihypertensive comedication (medication class).
Adverse effects, vital signs, and body weight were analysed by descriptive analyses. All adverse effects were coded according to MedDRA.
Results
Patients
A total of 772 physicians (general practitioners, internists, diabetologists) participated in CAMUS and documented 4005 patients with essential hypertension, overweight/obesity, and/or metabolic syndrome. Complete data sets were available for 3939 patients (98%). Median observation time was 64 days. Only 87 patients (2%) were discontinued before the end of the 8-week period, 0.5% because of adverse events.
Demographics and diagnoses
Of the 4005 patients, aged 20-93 years (median 61 years), 49% were female. Average height was 170 cm and body weight was 86 kg (BMI ¼ 30.5 kg/m 2 ), indicating that the vast majority of patients were overweight or obese. Moxonidine was started as first-time antihypertensive treatment in 777 (19%) newly diagnosed patients with essential hypertension. The majority of patients had moderate hypertension, whereas metabolic syndrome was present in just over half of the patients (Table 2) . While physicians diagnosed overweight/obesity in 80% of patients, the actual prevalence based on BMI was 92% (BMI425 kg/m 2 ¼ 92%, BMI430 kg/m 2 ¼ 48%). Concomitant cardiovascular diseases were leftventricular hypertrophy in 35% of the patients, followed by coronary artery heart disease (25%). Congestive heart failure, most often of NYHA class II, was present in 19% of the patients. Triglycerides were elevated in 2732 patients (68%), and 1986 patients (50%) had low HDL cholesterol.
Some risk factors for metabolic syndrome (apart from obesity) were more common in obese patients. This was most striking for elevated triglycerides, 
Antihypertensive medication
Moxonidine was most commonly used as 0.3 mg/ day (65%), followed by 0.4 mg/day (26%). During the observation period, the proportion of patients with 0.4 mg/day increased to 38%, while the proportion of patients with the 0.6 mg/day dose increased from 3.5 to 10%. Previous antihypertensive treatment was documented in 78% of all patients (ACE inhibitors 52%, diuretics 36%, b-blockers 34%, calcium channel blockers 29%). The majority of patients received moxonidine as supplemental therapy to their existing antihypertensive medication (73%). Concomitant antihypertensive medications given at initial observation were ACE inhibitors (50%), diuretics (36%), b-blockers (30%), Ca-antagonists (26%), alpha-1-receptor blockers (6%), and other substances (9%). There was little change in the comedication over the 8-week observation period.
Blood pressure and heart rate
There was a marked reduction in systolic (26.9715.1 mmHg; 95% CI: 26.4-27.3) and diastolic (13.279.5 mmHg; 95% CI: 12.9-13.5) blood pressure ( Figure 1 , Table 3 ). Patients with the highest blood pressure experienced the greatest reduction in blood pressure ( Figure 2 , Table 3 ). The blood pressure reduction was similar in patients with and without the metabolic syndrome. Blood pressure reduction was successful for patients in all weight classes (BMI, see Table 3 ). Likewise, blood pressure reduction was similar in patients with congestive heart failure, with or without previous antihypertensive therapy, or antihypertensive comedication.
Response to moxonidine (diastolic pressure o90 mmHg and/or reduction in diastolic pressure 410 mmHg) was seen in 3764 (94%) There was a modest reduction in heart rate from 79.2 þ 9.8 bpm at baseline to 74.0 þ 7.5 bpm at 8 weeks. The mean change in heart rate was À5.2 þ 8.2 (95% CI: À5.0 to À5.5). The decrease in heart rate in patients with severe hypertension was greater than in patients with mild hypertension (À6.0 þ 9.6 bpm; 95% CI: À5.4 to À6.5 vs À4.3 þ 7.4 bpm; 95% CI: À3.7 to À4.8). The reduction in heart rate in patients with metabolic syndrome was similar to that in the whole population. 
Body weight, BMI, and waist-to-hip Ratio (WHR)
At the end of the 8-week observation period, patients lost an average of 1.4 þ 2.9 kg (0.5 þ 1.0 kg/ m 2 BMI change). This change was independent of sex or the presence of the metabolic syndrome. The reduction in body weight was greater in obese (À1.873.5 kg) vs normal-weight (À0.071.9 kg) and overweight patients (À1.172.1 kg); weight reduction by baseline BMI category is presented in more detail in Figure 3 . There was no change of WHR and girth over the observation period.
Management decisions
While similar doses of moxonidine were used in patients with and without metabolic syndrome, the latter were more likely to be on antihypertensive comedication (Figure 4) . Combination therapy was more common in patients with severe (80%) than with moderate (70%) or mild (68%) hypertension. The proportion of patients with the 0.4 mg/day dose increased from 24% in patients with mild to 38% in patients with severe hypertension. With increasing severity of blood pressure, all antihypertensive classes were used more often, especially diuretics (mild: 30%, severe: 42%), calcium channel blockers (mild 22%, severe 33%), and alpha-1-receptor blockers (mild 4.2%, severe 7.6%). In contrast, the ACE inhibitors were used similarly in mild (51%), moderate (48%), and severe (54%) hypertension. At the final visit, physicians reported that they intended to continue moxonidine in 96% of all patients.
Adverse events
Adverse events were reported in 54 (1.3%) of 4005 patients. The most common side effects were dry mouth (0.5%) and headaches (0.2%). Drowsiness, vertigo, and nausea were reported in 1% of patients; all other side effects were reported at less than 0.1%. No adverse effects unknown for moxonidine were noted. Five severe adverse events (0.1%) were reported (congestive heart failure, cholelithiasis, haemorrhagic stroke, hyperventilation, lower limb fracture). None of these were seen as being related to moxonidine by the treating physician. No lethality was reported.
Discussion
While the use of moxonidine in patients with hypertension is well documented, the efficacy of this agent has not been previously evaluated in overweight/obese patients. This postmarketing surveillance study in over 4000 patients demonstrates that moxonidine effectively lowers blood pressure and is well tolerated by patients who are overweight/obese and/or have the metabolic syndrome. Systolic blood pressure was lowered by 26 mmHg, whereas diastolic pressure was lowered by 13 mmHg. Over 94% of patients responded to moxonidine, with diastolic blood pressure o90 mmHg or a reduction by 410 mmHg. These observations were similar to those of previous open and randomised-controlled studies. [24] [25] [26] As noted previously, the blood pressure lowering effect of moxonidine was greatest in those with the highest blood pressure 24 and response was similar in patients with and without the metabolic syndrome. The low side-effect profile of moxonidine is documented by the low rate of adverse events (1.3%) and the low rate of discontinuation (2.2%) during the course of the study. This corroborates results from a comparative study regarding tolerability of moxonidine versus nitrendipine in hypertensive patients with renal failure. 27 In this study, the decrease in creatinine clearance and the increase in serum creatinine during 24 weeks of add-on treatment were significantly lower for moxonidine than for nitrendipine.
Although three out of four patients were on combination therapy, only 31% of patients without diabetes reached the target blood pressure of o140/ 90 mmHg. In patients with diabetes, the lower target of o130/80 was reached by only 3.6%. These figures are similar to recent reports in other European countries of rather poor blood pressure control in general practice. 28 Poor control may be attributable in part both to poor compliance 29 and inadequate familiarity with current guidelines. 30 On the other hand, it must be noted that due to the rather short duration of the study, the blood pressure plateau may not have been reached in all patients.
The high rate of combination therapy (73%) is similar to that noted in previous studies. 11 As expected, high-risk patients with more severe hypertension and those with the metabolic syndrome 8 were more likely to be on combination therapy, whereby ACE inhibitors and diuretics were used most often.
Interestingly, body weight decreased by 1.4 kg over the observation period. This observation is in line with previous observations with moxonidine. 31, 32 Whether or not this is favourable, albeit a modest effect on body weight is related to the positive metabolic effects observed with moxonidine in previous studies (improvement in insulin sensitivity, reduction in plasma leptin levels and serum triglycerides), 33 remains to be determined. In summary, moxonidine effectively lowers blood pressure in overweight and obese patients with and without the metabolic syndrome and is well tolerated. Moxonidine also appears to have a favourable effect on body weight. Patients with metabolic syndrome are most often treated with a combination therapy that includes ACE inhibitors and diuretics. Nevertheless, despite the use of combination therapy, target blood pressure is only achieved in 30% of hypertensive patients and in only 3% of patients with diabetes.
